Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 April 2025
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 February 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2025
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 January 2025
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 15 January 2025Published: 12 May 2021
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2024
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 October 2024
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 September 2024
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)Product type:GuidanceProgramme:NICE guidelinePublished: 6 March 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Jaundice in newborn babies under 28 days (CG98)Product type:GuidanceProgramme:Clinical guidelineLast updated: 31 October 2023Published: 19 May 2010
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2022
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Eltrombopag for treating chronic immune thrombocytopenia (TA293)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 24 July 2013
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 27 April 2011
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (MTG28)Product type:GuidanceProgramme:Medical technologies guidancePublished: 2 March 2016
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 28 January 2015
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Sickle cell disease: managing acute painful episodes in hospital (CG143)Product type:GuidanceProgramme:Clinical guidelinePublished: 27 June 2012
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)Product type:AdviceProgramme:Medtech innovation briefingPublished: 30 September 2015
Autoimmune haemolytic anaemia: rituximab (ESUOM39)Product type:AdviceProgramme:Evidence summaryPublished: 10 February 2015
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)Product type:AdviceProgramme:Evidence summaryPublished: 21 October 2014
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 June 2025
Suspected sepsis: recognition, diagnosis and early managementStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 August 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2025
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 December 2025
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]Status:Awaiting developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canakinumab for untreated Schnitzler syndrome [ID4063]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]Status:Topic selectionProgramme:Health technology evaluationExpected publication date: TBC
Helge for detecting haemolysisStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Spectra Optia for plasma exchange, (MT828)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC